ResearcherTranslational Genomics Research InstituteNo recent work listed
Glen J. Weiss
Matched on ORCID iD 0000-0002-6067-597X; OpenAlex author ID A5080669646. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper
Papers 6
- Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-019-00763-x↗
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-017-0525-1↗
- A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. First author DOI 10.21037/jgo.2017.09.05↗
- Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1097/coc.0b013e3182467a13↗
- Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Co-author DOI 10.1371/journal.pone.0043192↗
- No miR quirk: dysregulation of microRNAs in pancreatic ductal adenocarcinoma. Last author DOI 10.2174/2211536611201010049↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vivek Khemka · 2 shared papers, 2018–2019 · strength 0.20
- Paper Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcin… DOI 10.1007/s10637-019-00763-x↗
- Paper Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. DOI 10.1007/s10637-017-0525-1↗
- Ramesh K. Ramanathan · 3 shared papers, 2012–2017 · strength 0.11
- Paper A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic … DOI 10.21037/jgo.2017.09.05↗
- Paper Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic … DOI 10.1097/coc.0b013e3182467a13↗
- Paper Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. DOI 10.1371/journal.pone.0043192↗
- Daniel D. Von Hoff · 3 shared papers, 2012–2017 · strength 0.11
- Paper A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic … DOI 10.21037/jgo.2017.09.05↗
- Paper Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic … DOI 10.1097/coc.0b013e3182467a13↗
- Paper Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. DOI 10.1371/journal.pone.0043192↗
- Michael T. Barrett · 2 shared papers, 2012–2017 · strength 0.08
- N.V. Rajeshkumar · 1 shared paper, 2017 · strength 0.06
- Gayle Jameson · 1 shared paper, 2017 · strength 0.06
- Manuel M. Hidalgo · 1 shared paper, 2017 · strength 0.06
- Anirban Maitra · 1 shared paper, 2017 · strength 0.06
- Anna E. Szafranska-Schwarzbach · 1 shared paper, 2012 · strength 0.04
- Philip Yue-Cheng Cheung · 1 shared paper, 2012 · strength 0.04
- Bernard F. Andruss · 1 shared paper, 2012 · strength 0.04
- Daruka Mahadevan · 1 shared paper, 2013 · strength 0.04
- Mitesh J. Borad · 1 shared paper, 2012 · strength 0.02
- Winnie S. Liang · 1 shared paper, 2012 · strength 0.02
- Haiyong Han · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.